The Impact of an Early Ibuprofen Treatment Protocol on the Incidence of Surgical Ligation of the Ductus Arteriosus

ABSTRACT

This study sought to determine whether early treatment of premature infants with ibuprofen would result in a reduced incidence of surgical ligation of patent ductus arteriosus. Secondary outcomes included duration of hospitalization, assisted ventilation and supplemental oxygen, mortality rate, persistent patent ductus arteriosus (PDA), hypotension, intraventricular hemorrhage, and intestinal perforation. Outcomes among 105 very low-birth-weight (VLBW) infants managed by clinical use of indomethacin were compared with outcomes of 80 infants treated under a standardized protocol for ibuprofen therapy on the first day of life among infants <25 weeks estimated gestational age (EGA) and among infants of 25 to 28 weeks EGA with respiratory distress syndrome or history of antenatal steroids. The incidence of PDA ligation was significantly lower among the early ibuprofen group than among the clinical indomethacin group (0/80 versus 9/105, p = 0.0056). No differences were found in secondary outcomes. The effect persisted (p = 0.0100 to 0.0153) when corrected for birth weight, EGA, gender, Apgar scores, initial pH and base deficit, transport from another hospital, surfactant treatment, and need for assisted ventilation. In our neonatal intensive care unit, the incidence of PDA ligation among VLBW infants decreased after adoption of an early ibuprofen treatment protocol.

Indomethacin - ibuprofen - ductus arteriosus - PDA - ligation

REFERENCES

• 1 Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld C R. Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less.  Pediatrics. 2006;  117 1113-1121
• 2 Hermes-DeSantis E R, Clyman R I. Patent ductus arteriosus: pathophysiology and management.  J Perinatol. 2006;  26(suppl 1) S14-S18 discussion S22-S23
• 3 Cowan F. Indomethacin, patent ductus arteriosus, and cerebral blood flow.  J Pediatr. 1986;  109 341-344
• 4 Liem K D, Hopman J CW, Kollée L AA, Oeseburg B. Effects of repeated indomethacin administration on cerebral oxygenation and haemodynamics in preterm infants: combined near infrared spectrophotometry and Doppler ultrasound study.  Eur J Pediatr. 1994;  153 504-509
• 5 Kang N S, Yoo K H, Cheon H et al.. Indomethacin treatment decreases renal blood flow velocity in human neonates.  Biol Neonate. 1999;  76 261-265
• 6 Coombs R C, Morgan M E, Durbin G M, Booth I W, McNeish A S. Gut blood flow velocities in the newborn: effects of patent ductus arteriosus and parenteral indomethacin.  Arch Dis Child. 1990;  65(10 Spec No) 1067-1071
• 7 Akima S, Kent A, Reynolds G J, Gallagher M, Falk M C. Indomethacin and renal impairment in neonates.  Pediatr Nephrol. 2004;  19 490-493
• 8 Attridge J T, Clark R, Walker M W, Gordon P V. New insights into spontaneous intestinal perforation using a national data set: (1) SIP is associated with early indomethacin exposure.  J Perinatol. 2006;  26 93-99
• 9 Fujii A M, Brown E, Mirochnick M, O'Brien S, Kaufman G. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus.  J Perinatol. 2002;  22 535-540
• 10 Fowlie P W, Davis P G. Prophylactic indomethacin for preterm infants: a systematic review and meta-analysis.  Arch Dis Child Fetal Neonatal Ed. 2003;  88 F464-F466
• 11 Pinhiero J M, Schulman J. Increasing incidence of patent ductus arteriosus (PDA) and PDA ligation in very low birth weight neonates [abstract].  Paediatric Academic Societies Annual Meeting. 2005;  , Abstract 57 583
• 12 Van Overmeire B, Smets K, Lecoutere D et al.. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus.  N Engl J Med. 2000;  343 674-681
• 13 Lago P, Bettiol T, Salvadori S et al.. Safety and efficacy of ibuprofen versus indomethacin in preterm infants treated for patent ductus arteriosus: a randomised controlled trial.  Eur J Pediatr. 2002;  161 202-207
• 14 Su P-H, Chen J-Y, Su C-M, Huang T C, Lee H S. Comparison of ibuprofen and indomethacin therapy for patent ductus arteriosus in preterm infants.  Pediatr Int. 2003;  45 665-670
• 15 Thomas R L, Parker G C, Van Overmeire B, Aranda J V. A meta-analysis of ibuprofen versus indomethacin for closure of patent ductus arteriosus.  Eur J Pediatr. 2005;  164 135-140
• 16 Aranda J V, Thomas R. Systematic review: intravenous ibuprofen in preterm newborns.  Semin Perinatol. 2006;  30 114-120
• 17 Su B-H, Lin H-C, Chiu H-Y et al.. Comparison of ibuprofen and indomethacin for early-targeted treatment of patent ductus arteriosus in extremely premature infants: a randomised controlled trial.  Arch Dis Child Fetal Neonatal Ed. 2008;  93 F94-999
• 18 Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus.  J Pediatr. 1997;  131 549-554
• 19 Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli F F. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus.  J Pediatr. 1999;  135 733-738
• 20 Patel J, Roberts I, Azzopardi D, Hamilton P, Edwards A D. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus.  Pediatr Res. 2000;  47 36-42
• 21 Romagnoli C, De Carolis M P, Papacci P et al.. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates.  Clin Pharmacol Ther. 2000;  67 676-683
• 22 Varvarigou A, Bardin C L, Beharry K, Chemtob S, Papageorgiou A, Aranda J V. Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants.  JAMA. 1996;  275 539-544
• 23 Van Overmeire B, Follens I, Hartmann S et al.. Treatment of patent ductus arteriosus with ibuprofen.  Arch Dis Child Fetal Neonatal Ed. 1997;  76 F179-F184
• 24 De Carolis M P, Romagnoli C, Polimeni V et al.. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants.  Eur J Pediatr. 2000;  159 364-368
• 25 Dani C, Bertini G, Reali M F et al.. Prophylaxis of patent ductus arteriosus with ibuprofen in preterm infants.  Acta Paediatr. 2000;  89 1369-1374
• 26 Van Overmeire B, Allegaert K, Casaer A et al.. Prophylactic ibuprofen in premature infants: a multicentre, randomised, double-blind, placebo-controlled trial.  Lancet. 2004;  364 1945-1949
• 27 Dani C, Bertini G, Pezzati M IntraVentricular Ibuprofen Study Group et al. Prophylactic ibuprofen for the prevention of intraventricular hemorrhage among preterm infants: a multicenter, randomized study.  Pediatrics. 2005;  115 1529-1535
• 28 Shah S S, Ohlsson A. Ibuprofen for the prevention of patent ductus arteriosus in preterm and/or low birth weight infants.  Cochrane Database Syst Rev. 2006;  CD004213
• 29 Koehne P S, Bein G, Alexi-Meskhishvii V et al.. Patent ductus arteriosus in very low birthweight infants: complications of pharmacologic and surgical treatment.  J Perinat Med. 2001;  29 327-334
• 30 Moin F, Kennedy K A, Moya F R. Risk factors predicting vasopressor use after patent ductus arteriosus ligation.  Am J Perinatol. 2003;  20 313-320
• 31 Noori S, Friedlich P, Seri I, Wong P. Changes in myocardial function and hemodynamics after ligation of the ductus arteriosus in preterm infants.  J Pediatr. 2007;  150 597-602
• 32 Kabra N S, Schmidt B, Roberts R S, Doyle L W, Papile L, Fanaroff A. Trial of Indomethacin Prophylaxis in Preterms Investigators . Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms.  J Pediatr. 2007;  150 229-234, 234, e1
• 33 Chorne N, Leonard C, Piecuch R, Clyman R I. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity.  Pediatrics. 2007;  119 1165-1174
• 34 Kluckow M, Evans N. Low superior vena cava flow and intraventricular haemorrhage in preterm infants.  Arch Dis Child Fetal Neonatal Ed. 2000;  82 F188-F194
• 35 Osborn D A, Evans N, Kluckow M. Effect of early targeted indomethacin on the ductus arteriosus and blood flow to the upper body and brain in the preterm infant.  Arch Dis Child Fetal Neonatal Ed. 2003;  88 F477-F482
• 36 Kluckow M, Evans N. Ductal shunting, high pulmonary blood flow, and pulmonary hemorrhage.  J Pediatr. 2000;  137 68-72
• 37 Sarkar S, Dechert R, Schumacher R E, Donn S M. Is refractory hypotension in preterm infants a manifestation of early ductal shunting?.  J Perinatol. 2007;  27 353-358
• 38 Alfaleh K, Smyth J A, Roberts R S et al.. Prevention and 18-month outcomes of serious pulmonary hemorrhage in extremely low birth weight infants: results from the trial of indomethacin prophylaxis in preterms.  Pediatrics. 2008;  121 e233-e238
• 39 El-Khuffash A F, Molloy E J, Walsh K et al.. Influence of a patent ductus arteriosus on cardiac troponin T levels in preterm infants.  J Pediatr. 2008;  153 350-353
• 40 El-Khuffash A, Barry D, Walsh K, Davis P G, Molloy E J. Biochemical markers may identify preterm infants with a patent ductus arteriosus at high risk of death or severe intraventricular haemorrhage.  Arch Dis Child Fetal Neonatal Ed. 2008;  93 F407-F412
• 41 Aranda J V, Clyman R, Cox B et al.. A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen L-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72 hours of birth in extremely low-birth-weight infants.  Am J Perinatol. 2009;  26 235-245